newsfilter
← Latest News
GlobeNewswire·

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage